查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1703382

循环肿瘤细胞市场－全球产业规模、份额、趋势、机会和预测（按产品、技术、地区和竞争细分，2020-2030 年）

Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球循环肿瘤细胞 (CTC) 市值为 69.6 亿美元，预计到 2030 年将达到 106.3 亿美元，预测期内年复合成长率(CAGR) 为 7.52%。受早期癌症检测需求不断增长、个人化医疗的广泛应用以及液体活检技术的重大进步的推动，市场正在经历大幅增长。

市场概览
预测期 2026-2030
2024年市场规模 69.6亿美元
2030年市场规模 106.3亿美元
2025-2030 年复合年增长率 7.52%
成长最快的领域 试剂盒和试剂
最大的市场 北美洲

循环肿瘤细胞（从原发性肿瘤脱离并进入血液的癌细胞）是评估癌症进展和转移风险的重要生物标记。检测和分析 CTC 的能力重塑了癌症诊断和治疗监测，使这些技术成为不断发展的肿瘤学领域的核心工具。

关键市场驱动因素

全球医疗保健产业的扩张

主要市场挑战

CTC技术成本高

主要市场趋势

非侵入性诊断解决方案的采用率不断上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球循环肿瘤细胞市场的影响

第五章：全球循环肿瘤细胞市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 副产品（试剂盒和试剂、采血管、设备或系统）
    • 依技术分类（CTC 检测和富集方法、CTC 直接检测方法、CTC 分析）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美循环肿瘤细胞市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲循环肿瘤细胞市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太循环肿瘤细胞市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲循环肿瘤细胞市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲循环肿瘤细胞市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球循环肿瘤细胞市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • QIAGEN NV
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 15903

Global circulating tumor cells (CTCs) market was valued at USD 6.96 billion in 2024 and is projected to reach USD 10.63 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.52% during the forecast period. The market is experiencing substantial growth, fueled by increasing demand for early cancer detection, the expanding adoption of personalized medicine, and significant advancements in liquid biopsy technologies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.96 Billion
Market Size 2030USD 10.63 Billion
CAGR 2025-20307.52%
Fastest Growing SegmentKits & Reagents
Largest MarketNorth America

Circulating tumor cells-cancerous cells that detach from primary tumors and enter the bloodstream-serve as crucial biomarkers for assessing cancer progression and the risk of metastasis. The ability to detect and analyze CTCs has reshaped cancer diagnostics and treatment monitoring, positioning these technologies as central tools in the evolving landscape of oncology.

Key Market Drivers

Expansion of the Global Healthcare Industry

The expansion of the global healthcare industry is playing a pivotal role in propelling the CTCs market forward. In response to the growing global cancer burden, institutions like the World Health Organization (WHO) have introduced initiatives such as the Guide to Cancer Early Diagnosis, which promotes timely detection and improved access to cancer care.

Healthcare systems are increasingly embracing precision medicine and early detection strategies to improve patient outcomes and reduce long-term treatment costs. CTCs offer a non-invasive and dynamic approach to cancer diagnostics by enabling the real-time tracking of tumor evolution, therapeutic response, and metastatic spread. Their ability to reveal the molecular characteristics of tumors makes them indispensable tools for guiding targeted therapy development and implementation.

The global rise in cancer prevalence further intensifies the need for efficient diagnostic tools. CTC-based technologies provide actionable insights that support the development of individualized treatment plans, making them a key component in the global push toward more precise and effective cancer care.

Key Market Challenges

High Costs Associated with CTC-Based Technologies

Despite their clinical benefits, CTC-based diagnostic technologies face challenges related to high implementation costs. Isolating and identifying circulating tumor cells-present in extremely low concentrations in the bloodstream-requires advanced equipment, including microfluidic devices, high-resolution imaging platforms, and sensitive molecular analysis tools. These systems are not only expensive to develop but also to deploy and maintain, making widespread clinical adoption difficult, particularly in cost-sensitive or resource-constrained healthcare environments. Beyond the cost of testing, substantial research and development (R&D) investments are needed to improve sensitivity, accuracy, and scalability of these technologies.

Key Market Trends

Rising Adoption of Non-Invasive Diagnostic Solutions

An increasing shift toward non-invasive diagnostics represents a significant trend shaping the global CTCs market. As healthcare providers and patients seek safer, faster, and more convenient alternatives to traditional biopsies, liquid biopsy solutions based on CTC detection are gaining momentum.

Liquid biopsy, enabled by a simple blood draw, allows for repeated, real-time monitoring of tumor dynamics without the discomfort or risks associated with tissue biopsies. This has led to the development and approval of tests such as the CellSearch Circulating Tumor Cell (CTC) Test, which is FDA-approved for assessing prognosis in patients with metastatic breast, prostate, or colorectal cancers. A low CTC count is associated with a more favorable outlook, while a high count may signal disease progression.

As this technology matures, liquid biopsy is becoming a cornerstone of precision oncology, offering dynamic insights into treatment effectiveness, disease progression, and early recurrence-all without disrupting patient comfort. This trend is fundamentally transforming how cancer is diagnosed and managed, driving the demand for innovative, non-invasive CTC-based diagnostics across global markets.

Key Market Players

  • QIAGEN N.V.
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Product:

  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems

Circulating Tumor Cells Market, By Technology:

  • CTC Detection & Enrichment Methods
  • CTC Direct Detection Methods
  • CTC Analysis

Circulating Tumor Cells Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Circulating Tumor Cells Market

5. Global Circulating Tumor Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
    • 5.2.2. By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Circulating Tumor Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
    • 6.3.2. Mexico Circulating Tumor Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
    • 6.3.3. Canada Circulating Tumor Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology

7. Europe Circulating Tumor Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Circulating Tumor Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
    • 7.3.2. Germany Circulating Tumor Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Circulating Tumor Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Circulating Tumor Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology

8. Asia Pacific Circulating Tumor Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Circulating Tumor Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Circulating Tumor Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
    • 8.3.3. South Korea Circulating Tumor Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
    • 8.3.4. Japan Circulating Tumor Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Circulating Tumor Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology

9. South America Circulating Tumor Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Circulating Tumor Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Circulating Tumor Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Circulating Tumor Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Circulating Tumor Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Circulating Tumor Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Circulating Tumor Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Circulating Tumor Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Circulating Tumor Cells Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bio-Techne Corp.
  • 15.3. Precision Medicine Group, LLC
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Natera, Inc.
  • 15.6. Illumina, Inc.
  • 15.7. Greiner Bio-One International GmbH
  • 15.8. Ikonisys Inc.
  • 15.9. Creative Bioarray
  • 15.10. Abnova Corporation

16. Strategic Recommendations

17. About Us & Disclaimer